Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B.

[1]  M. Esteban,et al.  Cellular and Biochemical Differences between Two Attenuated Poxvirus Vaccine Candidates (MVA and NYVAC) and Role of the C7L Gene , 2006, Journal of Virology.

[2]  A. Pascual-Montano,et al.  Host Response to the Attenuated Poxvirus Vector NYVAC: Upregulation of Apoptotic Genes and NF-κB-Responsive Genes in Infected HeLa Cells , 2006, Journal of Virology.

[3]  D. Montefiori,et al.  Studies using a viral challenge and CD8 T cell depletions on the roles of cellular and humoral immunity in the control of an SHIV-89.6P challenge in DNA/MVA-vaccinated macaques. , 2005, Virology.

[4]  Bjoern Peters,et al.  HLA class I-restricted responses to vaccinia recognize a broad array of proteins mainly involved in virulence and viral gene regulation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[5]  T. Ball,et al.  Elevated T cell counts and RANTES expression in the genital mucosa of HIV-1-resistant Kenyan commercial sex workers. , 2005, The Journal of infectious diseases.

[6]  R. Darnell,et al.  Apoptotic Cells Deliver Processed Antigen to Dendritic Cells for Cross-Presentation , 2005, PLoS biology.

[7]  D. Webster,et al.  Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[8]  G. Poli,et al.  Role of cytokines and chemokines in the regulation of innate immunity and HIV infection. , 2005, Molecular immunology.

[9]  D. Tscharke,et al.  Identification of poxvirus CD8+ T cell determinants to enable rational design and characterization of smallpox vaccines , 2005, The Journal of experimental medicine.

[10]  D. Webster,et al.  Differential Immunogenicity of Various Heterologous Prime-Boost Vaccine Regimens Using DNA and Viral Vectors in Healthy Volunteers1 , 2005, The Journal of Immunology.

[11]  M. Esteban,et al.  Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma. , 2004, Virus research.

[12]  J. Sirard,et al.  Attenuated poxviruses expressing a synthetic HIV protein stimulate HLA-A2-restricted cytotoxic T-cell responses. , 2004, Vaccine.

[13]  J. Whitton,et al.  The Rapidity with Which Virus-Specific CD8+ T Cells Initiate IFN-γ Synthesis Increases Markedly over the Course of Infection and Correlates with Immunodominance1 , 2004, The Journal of Immunology.

[14]  P. Earl,et al.  Highly Effective Control of an AIDS Virus Challenge in Macaques by Using Vesicular Stomatitis Virus and Modified Vaccinia Virus Ankara Vaccine Vectors in a Single-Boost Protocol , 2004, Journal of Virology.

[15]  M. Altfeld,et al.  Impact of intrapeptide epitope location on CD8 T cell recognition: implications for design of overlapping peptide panels , 2004, AIDS.

[16]  R. Sinden,et al.  Enhanced CD8+ T Cell Immune Responses and Protection Elicited against Plasmodium berghei Malaria by Prime Boost Immunization Regimens Using a Novel Attenuated Fowlpox Virus1 , 2004, The Journal of Immunology.

[17]  M. Albert.  Death-defying immunity: do apoptotic cells influence antigen processing and presentation? , 2004, Nature Reviews Immunology.

[18]  A. García-Sastre,et al.  Prime-Boost Immunization Schedules Based on Influenza Virus and Vaccinia Virus Vectors Potentiate Cellular Immune Responses against Human Immunodeficiency Virus Env Protein Systemically and in the Genitorectal Draining Lymph Nodes , 2003, Journal of Virology.

[19]  P. Earl,et al.  Different Patterns of Immune Responses but Similar Control of a Simian-Human Immunodeficiency Virus 89.6P Mucosal Challenge by Modified Vaccinia Virus Ankara (MVA) and DNA/MVA Vaccines , 2002, Journal of Virology.

[20]  John Stover,et al.  Can we reverse the HIV/AIDS pandemic with an expanded response? , 2002, The Lancet.

[21]  F. Rodríguez,et al.  Immunodominance in Virus-Induced CD8+ T-Cell Responses Is Dramatically Modified by DNA Immunization and Is Regulated by Gamma Interferon , 2002, Journal of Virology.

[22]  P. Rod Dunbar,et al.  Competition Between CTL Narrows the Immune Response Induced by Prime-Boost Vaccination Protocols1 , 2002, The Journal of Immunology.

[23]  Steven M. Wolinsky,et al.  Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes , 2002, Nature.

[24]  B. Graham.  Clinical trials of HIV vaccines. , 2002, Annual review of medicine.

[25]  D. Watkins,et al.  Potentiation of Simian Immunodeficiency Virus (SIV)-Specific CD4+ and CD8+ T Cell Responses by a DNA-SIV and NYVAC-SIV Prime/Boost Regimen , 2001, The Journal of Immunology.

[26]  M. Tsuji,et al.  Complete, long-lasting protection against malaria of mice primed and boosted with two distinct viral vectors expressing the same plasmodial antigen , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[27]  J. Heeney,et al.  Enhanced simian immunodeficiency virus-specific immune responses in macaques induced by priming with recombinant Semliki Forest virus and boosting with modified vaccinia virus Ankara. , 2001, Vaccine.

[28]  James G. Herndon,et al.  Control of a Mucosal Challenge and Prevention of AIDS by a Multiprotein DNA/MVA Vaccine , 2001, Science.

[29]  M. Esteban,et al.  A striking property of recombinant poxviruses: efficient inducers of in vivo expansion of primed CD8(+) T cells. , 2001, Virology.

[30]  A. Simon,et al.  Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. , 2000, Science.

[31]  P. Kourilsky,et al.  Recombinant viruses as a tool for therapeutic vaccination against human cancers. , 2000, Immunology letters.

[32]  C. Hallahan,et al.  Maintenance of Large Numbers of Virus-Specific CD8+ T Cells in HIV-Infected Progressors and Long-Term Nonprogressors , 2000, The Journal of Immunology.

[33]  J. Ramírez,et al.  Biology of Attenuated Modified Vaccinia Virus Ankara Recombinant Vector in Mice: Virus Fate and Activation of B- and T-Cell Immune Responses in Comparison with the Western Reserve Strain and Advantages as a Vaccine , 2000, Journal of Virology.

[34]  A. McMichael,et al.  Pre-clinical development of a multi-CTL epitope-based DNA prime MVA boost vaccine for AIDS. , 1999, Immunology letters.

[35]  J. Farber,et al.  Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. , 1999, Annual review of immunology.

[36]  J. Sodroski,et al.  The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. , 1998, Science.

[37]  J. Sodroski,et al.  Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody , 1998, Nature.

[38]  F. Falkner,et al.  The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. , 1998, Virology.

[39]  E. Paoletti,et al.  Recombinant Vaccine-Induced Protection against the Highly Pathogenic Simian Immunodeficiency Virus SIVmac251: Dependence on Route of Challenge Exposure , 1998, Journal of Virology.

[40]  B. Moss,et al.  Compact, synthetic, vaccinia virus early/late promoter for protein expression. , 1997, BioTechniques.

[41]  F. Lemonnier,et al.  HLA-A2.1–restricted Education and Cytolytic Activity of CD8+ T Lymphocytes from β2 Microglobulin (β2m) HLA-A2.1 Monochain Transgenic H-2Db β2m Double Knockout Mice , 1997, The Journal of experimental medicine.

[42]  S. Arya,et al.  Identification of RANTES, MIP-1α, and MIP-1β as the Major HIV-Suppressive Factors Produced by CD8+ T Cells , 1995, Science.

[43]  M. Esteban,et al.  Quantification of antigen specific CD8+ T cells using an ELISPOT assay. , 1995, Journal of immunological methods.

[44]  J. Margolick,et al.  Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. , 1995, The New England journal of medicine.

[45]  E. Paoletti,et al.  Induction of cytotoxic T lymphocytes by recombinant canarypox (ALVAC) and attenuated vaccinia (NYVAC) viruses expressing the HIV-1 envelope glycoprotein. , 1993, Virology.

[46]  M. Perkus,et al.  NYVAC: a highly attenuated strain of vaccinia virus. , 1992, Virology.